• Twitter
  • RSS
InterveXion Therapeutics
  • About Us
    • Overview
    • Management Team and Founders
    • Financial Conflict of Interest
  • Research & Development
    • Anti-Methamphetamine Products
    • Intellectual Property
    • Methamphetamine Use Statistics
  • Publications
    • Recent Publications
    • Anti-Methamphetamine Monoclonal Antibody
    • METH Vaccine
    • Anti-Phencyclidine Monoclonal Antibody
    • Review Articles
  • Contact Us
  • News
Select Page

NIDA Funds the First Clinical Trial of an Anti-Methamphetamine Antibody

Jul 15, 2011 | Anti-METH ch-mAb7F9, Grants, Uncategorized

A grant to fund the First in Human, Phase 1a clinical study of anti-METH ch-mAb7F9 was awarded to UAMS and InterveXion. This three year, $3 million, award will be used to test the safety of the chimeric antibody in healthy human volunteers.

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • InterveXion Licenses Asian Rights to Novel Anti-Methamphetamine Antibody to Ascent Therapeutics
  • InterveXion Awarded $8M to Fund Phase 2 Clinical Study of Anti-Methamphetamine Medication
  • STAMPOUT study to be conducted in METH users when funded
  • InterveXion Therapeutics Announces Fast Track Designation of IXT-m200 for Treatment of Methamphetamine Addiction
  • InterveXion Therapeutics, a UAMS Startup, Receives $14.5 Million to Develop Drug Therapies for Methamphetamine Users

Recent Comments

    Archives

    • January 2018
    • October 2017
    • June 2017
    • January 2016
    • January 2015
    • November 2014
    • February 2014
    • August 2013
    • July 2013
    • December 2012
    • November 2012
    • May 2012
    • April 2012
    • July 2011
    • April 2011
    • October 2009
    • September 2009
    • March 2005
    • January 2005

    Categories

    • Anti-METH ch-mAb7F9
    • Anti-METH Vaccine
    • Anti-PCP ch-mAb6B5
    • General News
    • Grants
    • Uncategorized

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    • Twitter
    • RSS
    © 2017 Intervexion